<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR891122-0086 </DOCNO><DOCID>fr.11-22-89.f2.A1085</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="41">[Docket No. 89N-0489]</ITAG><ITAG tagnum="52">Drug Export, Survanta  (Beractant, Surfactant TA)</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration, HHS.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingthat Ross Laboratories has filed an application requesting approval forthe export of the human drug Survanta<T4>#</T4> (beractant, Surfactant TA) to Italy and for further export tothe Federal Republic of Germany.</ITAG><ITAG tagnum="10"><T2>ADDRESSES: </T2>Relevant information on this application may be directedto the Dockets Management Branch (HFA-305), Food and Drug Administration,Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact personidentified below. Any future inquiries concerning the export of human drugsunder the Drug Export Amendments Act of 1986 should also be directed tothe contact person.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Mary F. Cooper, Division of DrugLabeling Compliance (HFD-313), Center for Drug Evaluation and Research,Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8073.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>The drug export provisions in section802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)provide that FDA may approve applications for the export of drugs thatare not currently approved in the United States. Section 802(b)(3)(B) ofthe act sets forth the requirements that must be met in an applicationfor approval. Section 802(b)(3)(C) of the act requires that the agencyreview the application within 30 days of its filing to determine whetherthe requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A)of the act requires that the agency publish a notice in the <T4>Federal Register</T4> within 10 days of the filing of an applicationfor export to facilitate public participation in its review of the application.To meet this requirement, the agency is providing notice that Ross Laboratories,625 Cleveland Ave., Columbus, OH 43215, has filed an application requestingapproval for the export of the drug Survanta<T4>#</T4> (beractant, Surfactant TA), to Italy and for further exportto the Federal Republic of Germany. This drug is indicated for use in acuterespiratory distress syndrome in neonates. The application was receivedand filed in the Center for Drug Evaluation and Research on September 14,1989, which shall be considered the filing date for purposes of the act.Interested persons may submit relevant information on the application tothe Dockets Management Branch (address above) in two copies (except thatindividuals may submit single copies) and identified with the docket numberfound in brackets in the heading of this document. These submissions maybe seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Mondaythrough Friday.The agency encourages any person who submits relevant information on theapplication to do so by December 4, 1989, and to provide an additionalcopy of the submission directly to the contact person identified above,to facilitate consideration of the information during the 30-day reviewperiod.This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec.803 (21 U.S.C 382)) and under authority delegated to the Commissioner ofFood and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluationand Research (21 CFR 5.44).<ITAG tagnum="21">Dated: November 14, 1989.</ITAG><ITAG tagnum="6">Sammie R. Young,</ITAG><ITAG tagnum="4">Acting Director, Office of Compliance, Center for Drug Evaluation andResearch.</ITAG><ITAG tagnum="40">[FR Doc. 89-27439 Filed 11-21-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>